Paradoxal effect of salbutamol in an in vitro model of bronchoprotection

Fundamental and Clinical Pharmacology

Volumn 19, Issue 2, 2005, Pages 179-186

  Girodet, P O ^a,b   Berger, P ^a,b   Martinez, B ^a,b   Marthan, R ^a,b   Advenier, C ^c   Molimard, M ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

adrenoceptor; Airway; Asthma; Hyperresponsiveness; Salbutamol; Smooth muscle

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ACETYLCHOLINE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL; NICARDIPINE; PROPRANOLOL; SALBUTAMOL;

ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CALCIUM CELL LEVEL; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA;

ACETYLCHOLINE; ALBUTEROL; ANIMALS; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GUINEA PIGS; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; TRACHEA; VASODILATOR AGENTS;

EID: 17144380412     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00320.x     Document Type: Article

References (31)

1. O'Byrne P.M., Kerstjens H.A. Inhaled beta 2-agonists in the treatment of asthma. N. Engl. J. Med. (1996) 335 886-888.
2. Rabe K.F., Schmidt D.T. Pharmacological treatment of asthma today. Eur. Respir. J. Suppl. (2001) 34 34s-40s.
3. Richter K., Janicki S., Jorres R.A., Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur. Respir. J. (2002) 19 865-871.
4. Phillips G.D., Finnerty J.P., Holgate S.T. Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5′-monophosphate in asthma. J. Allergy Clin. Immunol. (1990) 85 755-762.
5. Twentyman O.P., Finnerty J.P., Harris A., Palmer J., Holgate S.T. Protection against allergen-induced asthma by salmeterol. Lancet (1990) 336 1338-1342.
6. FitzGerald J.M., Chapman K.R., Della Cioppa G. et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J. Allergy Clin. Immunol. (1999) 103 427-435.
7. Dennis S.M., Sharp S.J., Vickers M.R. et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet (2000) 355 1675-1679.
8. Cheung D., Timmers M.C., Zwinderman A.H., Bel E.H., Dijkman J.H., Sterk P.J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N. Engl. J. Med. (1992) 327 1198-1203.
9. Booth H., Fishwick K., Harkawat R., Devereux G., Hendrick D.J., Walters E.H. Changes in methacholine induced bronchoconstriction with the long-acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax (1993) 48 1121-1124.
10. Booth H., Bish R., Walters J., Whitehead F., Walters E.H. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax (1996) 51 1100-1104.
11. Bhagat R., Swystun V.A., Cockcroft D.W. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J. Allergy Clin. Immunol. (1996) 97 47-52.
12. Aziz I., Tan K.S., Hall I.P., Devlin M.M., Lipworth B.J. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur. Respir. J. (1998) 12 580-584.
13. Gustafsson B., Persson C.G. Effect of different bronchodilators on airway smooth muscle responsiveness to contractile agents. Thorax (1991) 46 360-365.
14. Berger P., Perng D.W., Thabrew H. et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J. Appl. Physiol. (2001) 91 1372-1379.
15. Manara L., Badone D., Baroni M. et al. Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br. J. Pharmacol. (1996) 117 435-442.
16. De Ponti F., Gibelli G., Croci T., Arcidiaco M., Crema F., Manara L. Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A. Br. J. Pharmacol. (1996) 117 1374-1376.
17. Berger P., Tunon-De-Lara J.M., Savineau J.P., Marthan R. Selected contribution: tryptase-induced PAR-2-mediated Ca(2+) signaling in human airway smooth muscle cells. J. Appl. Physiol. (2001) 91 995-1003.
18. Roux E., Hyvelin J.M., Savineau J.P., Marthan R. Calcium signaling in airway smooth muscle cells is altered by in vitro exposure to the aldehyde acrolein. Am. J. Respir. Cell Mol. Biol. (1998) 19 437-444.
19. Molimard M., Martin C.A., Naline E., Hirsch A., Advenier C. Contractile effects of bradykinin on the isolated human small bronchus. Am. J. Respir. Crit. Care Med. (1994) 149 123-127.
20. Templeton A.G., Chapman I.D., Chilvers E.R., Morley J., Handley D.A. Effects of S-salbutamol on human isolated bronchus. Pulm. Pharmacol. Ther. (1998) 11 1-6.
21. Finnerty J.P., Howarth P.H. Paradoxical bronchoconstriction with nebulized albuterol but not with terbutaline. Am. Rev. Respir. Dis. (1993) 148 512-513.
22. Facchini G., Antonicelli L., Cinti B., Bonifazi F., Massei V. Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators. Monaldi Arch. Chest Dis. (1996) 51 201-203.
23. Hauck R.W., Harth M., Schulz C., Prauer H., Bohm M., Schomig A. Effects of beta 2-agonist- and dexamethasone-treatment on relaxation and regulation of beta-adrenoceptors in human bronchi and lung tissue. Br. J. Pharmacol. (1997) 121 1523-1530.
24. Fanta C.H., Watson J.W., Lacouture P.G., Draren J.M. In vivo bronchodilator activity of nifedipine in the guinea pig. Am. Rev. Respir. Dis. (1987) 136 76-79.
25. Sarria B., Zhang Y., Naline E. et al. The nicardipine-isoprenaline interaction in human and guinea-pig isolated airways. Fundam. Clin. Pharmacol. (1994) 8 26-33.
26. Cuss F.M., Barnes P.J. The effect of inhaled nifedipine on bronchial reactivity to histamine in man. J. Allergy Clin. Immunol. (1985) 76 718-723.
27. Advenier C., Sarria B., Naline E., Puybasset L., Lagente V. Contractile activity of three endothelins (ET-1, ET-2 and ET-3) on the human isolated bronchus. Br. J. Pharmacol. (1990) 100 168-172.
28. Naline E., Candenas M.L., Palette C. et al. Effects of okadaic acid on the human isolated bronchus. Eur. J. Pharmacol. (1994) 256 301-309.
29. Stewart A.G., Tomlinson P.R., Wilson J.W. Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation. Br. J. Pharmacol. (1997) 121 361-368.
30. Takeda M., Obara K., Mizusawa T. et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther. (1999) 288 1367-1373.
31. Brahmadevara N., Shaw A.M., MacDonald A. Evidence against beta(3)-adrenoceptors or low affinity state of beta(1)-adrenoceptors mediating relaxation in rat isolated aorta. Br. J. Pharmacol. (2003) 138 99-106.